A small Raleigh-based startup hopes to shake up the chronic obstructive pulmonary disease (COPD) market with a treatment for an underserved target—airway mucus plugs. Aer Therapeutics closed a $36 million Series A Thursday to take its inhaled mucolytic to the clinic.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,